Makombe Simon D, Jahn Andreas, Tweya Hannock, Thambo Lameck, Yu Joseph Kwong-Leung, Hedt Bethany, Weigel Ralf, Nkhata Amon, Schouten Erik J, Kamoto Kelita, Harries Anthony D
Clinical HIV Unit, Ministry of Health, Lilongwe, Malawi.
World Hosp Health Serv. 2008;44(1):26-9.
Malawi is making good progress scaling up antiretroviral therapy (ART), but we do not know the levels of access of high-risk, disadvantaged groups such as prisoners. The aim of this study was to measure access and treatment outcomes of prisoners on ART at the national level.
A retrospective cohort study was conducted examining patient follow-up records from all 103 public sector ART clinics in Malawi, and observations were censored on 31 December, 2006.
By 31 December, 2006, a total of 81,821 patients had been started on ART. Of these, 103 (0.13%) were prisoners. At ART initiation, 93% of prisoners were in World Health Organization (WHO) clinical stage 3 or 4 while 7% started in stage 1 or 2 with a CD4-lymphocyte count of < or =250/mm3. Treatment outcomes by the end of December 2006 were as follows: 66 (64%) alive and on ART at their registration facility; 9 (9%) dead; 8 (8%) lost to follow-up; and 20 (19%) transferred out to another facility. The probability of being alive and on ART at 6 and 12 months was 82.5% and 77.7%.
In spite of the rapid scale-up of ART, only a small number of HIV-positive prisoners had accessed ART by the end of 2006. Treatment outcomes were good. Initiatives are now needed to improve access to HIV testing and ART in Malawi's prisons.
马拉维在扩大抗逆转录病毒疗法(ART)的推广方面取得了良好进展,但我们并不清楚诸如囚犯等高风险弱势群体的治疗可及性水平。本研究的目的是在国家层面衡量囚犯接受抗逆转录病毒治疗的可及性和治疗效果。
开展了一项回顾性队列研究,检查了马拉维所有103家公共部门抗逆转录病毒治疗诊所的患者随访记录,观察期截至2006年12月31日。
截至2006年12月31日,共有81,821名患者开始接受抗逆转录病毒治疗。其中,103名(0.13%)为囚犯。开始接受抗逆转录病毒治疗时,93%的囚犯处于世界卫生组织(WHO)临床3期或4期,而7%的囚犯以1期或2期开始治疗,其CD4淋巴细胞计数≤250/mm³。2006年12月底的治疗效果如下:66名(64%)在登记机构存活且仍在接受抗逆转录病毒治疗;9名(9%)死亡;8名(8%)失访;20名(19%)转至另一机构。在6个月和12个月时存活且仍在接受抗逆转录病毒治疗的概率分别为82.5%和77.7%。
尽管抗逆转录病毒疗法迅速扩大,但到2006年底,只有少数艾滋病毒阳性囚犯能够接受抗逆转录病毒治疗。治疗效果良好。现在需要采取举措,改善马拉维监狱中艾滋病毒检测和抗逆转录病毒治疗的可及性。